Engineers Gate Manager’s NRX Pharmaceuticals NRXP Stock Holding History

Engineers Gate Manager’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,521	Closed	-$121K	–	2174
2021 Q4	$121K	Buy	+2,521	New	+$182K	0.01%	1781

Other funds holding NRXP

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Engineers Gate Manager's NRXP Position: Q1 2022 in Review

Engineers Gate Manager sold out of NRX Pharmaceuticals (NRXP) in Q1 2022, closing a stake of 2,521 shares — an estimated $121K sold.

Engineers Gate Manager first reported a position in NRXP in Q4 2021 and held it in 1 quarter. The position peaked at $121K in Q4 2021. 34 funds tracked by Wall St. Rank hold NRXP as of Q1 2022.

Engineers Gate Manager reported no remaining NRX Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Engineers Gate Manager sold 2,521 NRX Pharmaceuticals shares in Q1 2022, an estimated $121K.
Engineers Gate Manager first reported a position in NRX Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Engineers Gate Manager's NRX Pharmaceuticals position peaked at $121K in Q4 2021.
34 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2022.

Based on Engineers Gate Manager's 13F filing for Q1 2022, filed 16 May 2022.